Survivorship and Patients Perspective
Weiping Liu, Mingzi Yang, Meng Wu, Lingyan Ping, Xiaopei Wang, Yuqin Song, Jun Zhu
Peking University Cancer Hospital & Institute
Background: Anemia has been proved to be a negative prognostic factor for non-Hodgkin lymphoma. This study was to determine whether the presence of anemia is a negative prognostic indicator for response to treatment and survival time in Hodgkin lymphoma (HL) patients.
Methods: Clinical data of HL patients undergoing chemotherapy with ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine) between January 2002 and January 2018 were collected. Chi-square test was performed to determine the effect of anemia on initial response to chemotherapy. Cox regression analyses were used to determine the associations of anemia and progression-free survival (PFS) and overall survival (OS).
Results: The incidence of pretreat anemia in HL patients was 18.9% (60/318). Complete remission rates were lower in patients with anemia than in those without anemia (55.9% vs. 83.2%, P < 0.001). After 34 months of follow-up, the 3-year PFS and OS rates in patients with anemia were lower than in those without anemia (86% vs. 68%, P < 0.001; 90% vs. 96%, P = 0.001; respectively). Multivariate analysis identified the independent significant predictor for OS included age (HR = 1.055, P < 0.001), anemia (HR = 2.995, P = 0.024) and extranodal involvement (HR = 2.988, P = 0.021).
Conclusions: Anemia at the time of diagnosis has a negative impact on the outcome of HL patients. Prospective clinical trials should be encouraged to evaluate the prognostic utility of anemia.